Delving into the Latest Updates on Herombopag Olamine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Hengqu, Hetrombopag, Hetrombopag olamine

+ [7]

Target

TPO receptor

Mechanism

TPO receptor agonists(Thrombopoietin receptor agonists)

Therapeutic Areas

Immune System DiseasesHemic and Lymphatic DiseasesOther Diseases+ [3]

Active Indication

Anemia, AplasticChronic thrombocytopeniaPurpura, Thrombocytopenic, Idiopathic+ [8]

Inactive Indication

Chronic idiopathic thrombocytopenic purpuraNon-Small Cell Lung CancerSecond Primary Neoplasms

Originator Organization

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Active Organization

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Inactive Organization

Atridia Pty Ltd.

Drug Highest PhaseApproved

First Approval Date

CN (16 Jun 2021),

Anemia, AplasticChronic thrombocytopeniaPurpura, Thrombocytopenic, Idiopathic

RegulationConditional marketing approval (CN), Special Review Project (CN), Orphan Drug (US), Priority Review (CN)

Login to view timeline

Structure/Sequence

Molecular FormulaC25H22N4O5

InChIKeyBDGGFTDRPHKXFC-QYQHSDTDSA-N

CAS Registry2600513-51-5

BACKGROUNDHetrombopag is a novel thrombopoietin receptor agonist that has shown an additive effect in stimulating platelet production when combined with recombinant human thrombopoietin (rhTPO). However, it remains unclear whether this combination can promote hematopoietic reconstruction after autologous stem cell transplant (ASCT).PURPOSETo compare the effect of rhTPO plus thrombopoietin receptor agonists (TPO-RA) versus rhTPO alone on hematopoietic recovery, adverse events, postoperative complications, and cost-effectiveness in patients with newly diagnosed multiple myeloma (NDMM) undergoing ASCT.METHODSA total of 67 consecutive NDMM patients who underwent ASCT at our hospital from January 2021 to May 2024 were included. Of these patients, 35 received a combination of rhTPO and the TPO-RA hetrombopag after stem cell reinfusion (observation group), whereas 32 patients received rhTPO alone (control group). Hematopoietic reconstitution between the two groups was compared.RESULTSBaseline clinical characteristics were similar between both groups. In the observation group, the median time to platelet recovery was 9 days after stem cell reinfusion, which was significantly shorter than that in the control group (P = .003). The mean number of platelet transfusions in the observation group was significantly lower than that in the control group (1.0 vs. 2.0 units, P = .034). All patients tolerated rhTPO and TPO-RA well, with no thrombotic events observed. Survival analysis showed no reduction in time to progression (TTP) and overall survival (OS) with the addition of TPO-RA. There were no statistical differences in the incidence of adverse events, drug expenses, and hospital stay between two groups (P > 0.05).CONCLUSIONSAlthough sample size and study design limit the data from this study, our findings suggest that the combination of TPO-RA (hetrombopag) and rhTPO enhances platelet recovery in comparison with rhTPO alone, without increasing adverse effects.

01 Dec 2024·British Journal of Haematology

Real‐world evidence of avatrombopag for the treatment of immune thrombocytopenia intolerant or ineffective to eltrombopag/hetrombopag

Article

Author: Li, Yun ; Zhou, Lu ; Liu, Xiao‐fan ; Gu, Cheng‐Yuan ; Dai, Jia‐wen ; Yin, Jie ; Yu, Zi‐Qiang ; Kong, Dan‐Qing ; Tian, Hong

SummaryDue to the limited real‐world research on the application of avatrombopag (AVA) for immune thrombocytopenia (ITP) in China, we evaluated the effectiveness and safety of AVA in clinical practice. We included 121 adult ITP patients treated with AVA across three medical centres. Based on the reasons for choosing AVA, these patients were divided into eltrombopag (ELT)/hetrombopag (HET) intolerance group (IG), and ELT/HET unresponsive group (UG). Compared with UG, more patients in IG had a history of liver disease and received fewer treatments before AVA. Amongst all patients, 83% had platelet response (≥30 × 109/L) after AVA and 62% achieved complete response (≥100 × 109/L, CR). Sixty‐two percent in IG and 56% in UG were able to discontinue more than one concomitant ITP medication. A total of 17 patients underwent multiple switches of thrombopoietin receptor agonists (TPO‐RAs), resulting in an 88% platelet response rate. Sixty‐three patients discontinued AVA, 27% were due to unaffordability. AVA was well tolerated in most patients. In the ITP population, AVA proved effective and safe, particularly in patients intolerant or unresponsive to ELT/HET. Patients benefited from TPO‐RAs switches, particularly those undergoing multiple switches. However, many patients struggled with the long‐term financial burden of AVA.

01 Nov 2024·Annals of Hematology

The effect of hetrombopag combined with conventional treatment on immune function and quality of life in patients with severe aplastic anemia

Article

Author: Wang, Shu-Wen ; Wang, Gu-Yun ; Liu, Dan ; Huang, Ying ; Tang, Rui-Mei ; Chen, Wen-Ting

This study aimed to investigate the effect of hetrombopag combined with conventional treatment on immune function in patients with severe aplastic anemia (SAA). Patients were categorized into the control group (n = 50, receiving conventional treatment only) and experimental group (n = 50, receiving hetrombopag combined with conventional treatment). Before treatment and at weeks 18, 24, and 52 after treatment, the two groups were compared in routine blood test indicators, natural killer (NK) cell activity, and peripheral blood inflammatory factor levels. The overall remission rate and incidence of adverse events were also compared between the two groups. Outpatient or telephone follow-up was performed before treatment and at weeks 18, 24, and 52 after treatment to observe patients' immune function, treatment outcome, quality of life, and adverse events. Hemoglobin (Hb), and platelet count (PLT) (P < 0.05), and a rise in NK cell activity (P < 0.05). Interleukin (IL-10) levels were significantly higher, while IL-6 levels were significantly lower in the experimental group compared to the control group (P < 0.05). After receiving the treatment, all scores of SF-36 domains in both groups were higher than before treatment, particularly with higher scores in the experimental group (P < 0.05). Hetrombopag combined with conventional treatment improved the immune function and hematopoiesis of patients with SAA.

100 Deals associated with Herombopag Olamine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	B02BX	DB16184

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Anemia, Aplastic	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	16 Jun 2021
Chronic thrombocytopenia	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	16 Jun 2021
Purpura, Thrombocytopenic, Idiopathic	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	16 Jun 2021

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic thrombocytopenia	Phase 3	-	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	23 Jan 2023
Purpura, Thrombocytopenic, Idiopathic	Phase 3	-	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	23 Jan 2023
Thrombocytopenia	Phase 3	US	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	11 Jan 2022
Thrombocytopenia	Phase 3	AU	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	11 Jan 2022
Thrombocytopenia	Phase 3	-	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	11 Jan 2022
Neoplasms	Phase 3	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Nov 2019
Refractory Severe Aplastic Anemia	Phase 3	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	05 Mar 2019
Chronic idiopathic thrombocytopenic purpura	Phase 1	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	29 Mar 2021
Solid tumor	Phase 1	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Nov 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ChiCTR2200062156 (ASH2024) Manual	Not Applicable	Hematopoietic stem cell transplantation	48	Hetrombopag	(capshbgiaw) = During the observation period, one patient experienced HAPG-related liver damage and another experienced HPAG-related kidney damage. No abnormality was found in the remaining patients. newgzubvoa (tprkxmewxs )	Positive	08 Dec 2024
ChiCTR2200062156 (ASH2024) Manual	Not Applicable	Hematopoietic stem cell transplantation	48	rhTPO (Historical control group)		Positive	08 Dec 2024
NCT03825744 (ASH2024) Manual	Phase 3	Anemia, Aplastic	240	Hetrombopag + IST	(eilxgamdil) = gnnwfuvrmf xscuochhdj (fpfmqghftt, 21.2 - 35.1) View more	Positive	07 Dec 2024
NCT03825744 (ASH2024) Manual	Phase 3	Anemia, Aplastic	240	Placebo + IST	(eilxgamdil) = suueaupolv xscuochhdj (fpfmqghftt, 6.2 - 21.3) View more	Positive	07 Dec 2024
ChiCTR2200057846 (ESMO2024) Manual	Phase 2	Solid tumor \| Thrombocytopenia	28	Hetrombopag 7.5 mg QD	(amepobkgbv) = rtnkmwgagv afrfmqacbg (znlbeyehlw ) View more	Positive	15 Sep 2024
EHA2024 Manual	Not Applicable	Thrombocytopenia	18	Hetrombopag	(wuzculyyzi) = None cmwpsqfqvb (oqolxjyzsj ) View more	Positive	14 May 2024
EHA2024 Manual	Not Applicable	Thrombocytopenia	22	Hetrombopag 5mg	xbeedwzuzb(rneajavqor) = pescravahc kmwumnohyz (nessvycnhg ) View more	Positive	14 May 2024
EHA2024 Manual	Not Applicable	Thrombocytopenia	22	Placebo	xbeedwzuzb(rneajavqor) = zfkegtupoh kmwumnohyz (nessvycnhg ) View more	Positive	14 May 2024
NCT05160857 (EHA2024) Manual	Not Applicable	Thrombocytopenia	23	Hetrombopag	(mkaynmozys) = skrnnobbhg qtiidgvafy (iuqmiovkhi ) View more	Positive	14 May 2024
EHA2024 Manual	Not Applicable	Anemia, Aplastic	21	Hetrombopag	(roongaspit) = wgloxsrmbt gfgfasicom (oqtpfwppaw ) View more	Positive	14 May 2024
EHA2024 Manual	Not Applicable	Anemia, Aplastic	21	Hetrombopage A	(roongaspit) = rnsbyhdktv gfgfasicom (oqtpfwppaw ) View more	Positive	14 May 2024
EHA2024 Manual	Phase 3	Thrombocytopenia Consolidation	32	Hetrombopag 5 mg	klgwstxmli(gueqoydjun) = iafxwttuiq yzsvnzeuxv (zpqcnblrob, 5.83 - 7.73) View more	Positive	14 May 2024
NCT06099925 (EHA 12024 \| EHA 22024) Manual	Phase 2	Thrombocytopenia	20	Hetrombopag 5mg	bcehdwdwjl(uxfkbceyuw) = bfhajiavgh szopnsbavw (zyiqlyubzg, 0.1812 - 0.5671) View more	Positive	14 May 2024
ASH2023	Not Applicable	Thrombocytopenia \| Multiple Myeloma \| Lymphoma	60	Hetrombopag	jbvkvfljii(eqftruntjg) = whwaqylioh inptslzbct (dopqijwjxa ) View more	-	11 Dec 2023